# Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%

> **NCT06321094** · — · COMPLETED · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 149 (actual)

## Conditions studied

- Acute Coronary Syndrome
- Heart Failure With Reduced Ejection Fraction

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06321094
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-31
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06321094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06321094, "Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06321094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*